Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis

Table 1 Basic demographic data of the included clinical trials

Study ID	First author	Ref.	Year of publish	Country of origin	Participant number	Dialysis mode
1	Abdul N Khan	[7]	1996	United States	97	HD and CAPD
2	Kai Ming Chow	[8]	2010	China	87	CAPD
3	Ismail Hamdi Kara	[9]	2004	Turkey	34	HD
4	Baris Afsar	[10]	2009	Turkey	188	HD
5 (ID) 6 (IM)	Andre F Charest	[11]	2000	Canada	97	HD
7	Yao-Lung Liu	[12]	2005	Taiwan	69	HD and CAPD
8	Nancy M Waite	[13]	1995	Canada	77	HD
9	Salwa Ibrahim	[14]	2006	Egypt	29	HD
10	Shih-Yi Lin	[15]	2012	Taiwan	156	HD and CAPD
11	Dede sit	[16]	2007	Turkey	64	HD
12	Gerald DaRoza	[17]	2003	Canada	165	CKD
13	Jamshid Roozbeh	[18]	2005	Iran	62	HD
14	Khalid Al Saran	[19]	2014	Saudi Arabia	144	HD
15	Kevin S Eardley	[20]	2002	United Kingdom	105	HD
16	Sabahattin Ocak	[21]	2008	Turkey	49	HD
17	EO Morais	[22]	2007	Brazil	70	CKD
18	Sh Taheri	[23]	2005	Iran	125	CKD (32), HD (93)
19	Carol Dacko	[24]	1996	United States	32	CAPD
20	Gerald M Fraser	[25]	1994	United States	59	HD and CAPD

CAPD: Continuous ambulatory peritoneal dialysis; HD: Hemodialysis; ID: Intra-dermal; IM: Intramuscular.

Table 2 Demography of the participants in the studies included in the meta-analysis

Author	Ref.	Age (mean ± SD)	Gender male (%)	Duration of dialysis (mo)
Abdul N Khan	[7]	47 ± 14 (CAPD)	26(55%; CAPD)	18 ± 23 (CAPD)
		51 ± 18 (HD)	26 (52%; HD)	56 ± 73 (HD)
Kai Ming Chow	[8]	60 ± 11	51/87 (59)	5.8 (median)
Ismail Hamdi Kara	[9]	44 ± 15	19 (56)	27 ± 15
Baris Afsar	[10]	NA (for total)	66 (35)	NA (for total)
Andre F Charest	[11]	52 ± 2 (ID)	73 (75)	3.4 ± 1.0 (ID)
		46 ± 2 (IM)		4.8 ± 2.0 (IM)
Yao-Lung Liu	[12]	52 ± 16 (CAPD)	28 (41)	43 ± 33 (CAPD)
		61 ± 11 (HD)		60 ± 49 (HD)
Nancy M Waite	[13]	NA (for total)	49 (64)	NA (for total)
Salwa Ibrahim	[14]	46 ± 11	19 (66)	80 ± 59
Shih-Yi Lin	[15]	NA(for total)	64/156(41)	NA
Dede sit	[16]	NA (for total)	31 (48)	NA (for total)
Gerald DaRoza	[17]	60 ± 15	106 (46)	NA
Jamshid Roozbeh	[18]	NA(for total)	37/62 (60)	NA
Khalid Al Saran	[19]	51 ± 15	78/66 (54)	40
Kevin S Eardley	[20]	61 ± 13	58/47 (55)	18
Sabahattin Ocak	[21]	54 ± 13	56/30 (65)	30 ± 18
EO Morais	[22]	54.5 (median)	40 (57)	26
Sh Taheri	[23]	50 ± 17	77 (62)	NA
Carol Dacko	[24]	NA (for total)	19 (59)	NA (for total)
Gerald M Fraser	[25]	NA (for total)	117 (58)	NA

SD: Standard deviation; CAPD: Continuous ambulatory peritoneal dialysis; HD: Hemodialysis; NA: Not available; ID: Intra-dermal; IM: Intramuscular.

Table 3 Vaccination information details in the included clinical trials

Author	Ref.	Vaccination mode	Vaccine type	Vaccine dose	Schedule (mo)
Abdul N Khan	[7]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, (2), 6
Kai Ming Chow	[8]	IM	Recombinant (Engerix-B)	40 mcg and 80 mcg	0, 1, 6
Ismail Hamdi Kara	[9]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, 2, 6
Baris Afsar	[10]	IM	Recombinant	-	0, 1, 2, 6
Andre F Charest	[11]	ID and IM	Recombinant (Engerix-B)	40 mcg (IM); 5 mcg (ID)	0, 1, 2, 6
Yao-Lung Liu	[12]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, 2, 6
Nancy M Waite	[13]	IM	Recombinant (Engerix-B)	40 mcg	0,1,2,6
Salwa Ibrahim	[14]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, 2, 6
Shih-Yi Lin	[15]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, 2, 6
Dede sit	[16]	IM	Recombinant (Hepavax)	40 mcg	0, 1, 2, 6
Gerald DaRoza	[17]	IM	Recombinant and plasma derived	20, 40 and 80 mcg	0, 1, 6
Jamshid Roozbeh	[18]	IM and ID	Recombinant (Herberbiovac-HB)	40 mcg (IM); 20 mcg (ID)	0, 1, 4
Khalid Al Saran	[19]	IM	Recombinant (Engerix-B)	40 mcg	0, 1, 2, 6
Kevin S Eardley	[20]	IM	Recombinant (Aventis MSD)	40 mcg	0, 1, 2, 12
Sabahattin Ocak	[21]	IM	Recombinant (Euvax-B)	40 mcg	0, 1, 2, 6
EO Morais	[22]	ID	Recombinant (Greencross)	2 × 5 mcg	16 injection within 8 wk
Sh Taheri	[23]	IM	Recombinant (Havana)	40 mcg	0, 1, 6
Carol Dacko	[24]	IM	Recombinant (Engerix)	40 mcg	0, 1, 2, 6
Gerald M Fraser	[25]	NA	Recombinant (Engerix-B)	20 mcg	0, 1, 2, 6

ID: Intra-dermal; IM: Intramuscular.